The tweet was deleted by the author.
But we saved everything 🙂.
Summit Therapeutics announced that Arcus Biosciences and Summit Therapeutics have entered into a clinical trial collaboration to evaluate casdatifan combined with ivonescimab in kidney cancer.
Data from this collaboration is expected to be generated by mid-2027.
View post on X Loading...
SMMT is trading at $14.74, just beneath the MA-20 ($14.76), below the MA-50 ($15.43), and significantly under the MA-200 ($17.40), reflecting persisting medium- and long-term bearish pressure despite some short-term stabilization. The Ichimoku Kijun sits at $14.49, placing immediate resistance above the current price. For near-term support, the MA-20 ($14.76) acts as the closest technical base, with key support at the MA-50 ($15.43). Resistance zones cluster at the Ichimoku Kijun ($14.49) as immediate resistance and further at the MA-100 ($16.96) as key resistance.
Momentum signals present a mixed picture: MACD on D1 remains bearish while ADX is neutral, indicating the move lacks strong conviction. RSI (47.67), CCI (–49.65), and D1 BBP (0.09, oversold) collectively point to a lack of buyer aggression and a market leaning toward seller dominance, though Stoch RSI shows a "Strong Buy" reading that diverges from the generally weak momentum backdrop. Over the past week, SMMT has risen $0.93 (6.73%) from the previous weekly close of $13.81, trading now at the very top of its weekly range, reflecting a recovery from the recent low. Weekly volatility stands at 12.09%, and the tone is one of sharp rebound rather than consolidation.
For the coming week, SMMT is expected to trade between $14.50 and $15.60, keeping within the recent volatility band and well above the 52-week low ($12.55) but distant from the 52-week high ($30.98). Given that all major weekly indicators (RSI-W1 "Sell", ADX-W1 "Neutral", MACD-W1 "Sell", MA-50-W1 "Sell") are bearish or neutral, the probability of a further price increase is very low (less than 20%), making a pullback the more likely scenario. Baseline case: SMMT consolidates sideways within $14.50–$15.60. Bullish scenario: a break above $15.60 could target higher resistances, but this is less probable. Bearish scenario: a drop below $14.50 would signal another test of support and possibly a return toward the low end of the recent range.
Earlier, analysts noted that Summit Therapeutics was exhibiting persistent bearish momentum despite brief rebound attempts. This article affirms that downside risks remain pronounced, and traders should closely monitor for renewed selling pressure if support levels are breached in the near term.